197 related articles for article (PubMed ID: 31987970)
1. The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo.
Paillas S; Then CK; Kilgas S; Ruan JL; Thompson J; Elliott A; Smart S; Kiltie AE
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):212-221. PubMed ID: 31987970
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitization
Groselj B; Ruan JL; Scott H; Gorrill J; Nicholson J; Kelly J; Anbalagan S; Thompson J; Stratford MRL; Jevons SJ; Hammond EM; Scudamore CL; Kerr M; Kiltie AE
Mol Cancer Ther; 2018 Feb; 17(2):381-392. PubMed ID: 28839000
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
5. FK228 sensitizes radioresistant small cell lung cancer cells to radiation.
Li H; Ma L; Bian X; Lv Y; Lin W
Clin Epigenetics; 2021 Feb; 13(1):41. PubMed ID: 33632300
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
Cuneo KC; Fu A; Osusky K; Huamani J; Hallahan DE; Geng L
Anticancer Drugs; 2007 Aug; 18(7):793-800. PubMed ID: 17581301
[TBL] [Abstract][Full Text] [Related]
7. Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice.
Tsai CL; Liu WL; Hsu FM; Yang PS; Yen RF; Tzen KY; Cheng AL; Chen PJ; Cheng JC
Hepatology; 2018 Feb; 67(2):586-599. PubMed ID: 28646552
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer.
Zhu L; Wu K; Ma S; Zhang S
Tumori; 2015; 101(3):257-62. PubMed ID: 25953446
[TBL] [Abstract][Full Text] [Related]
9. R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin.
Safari M; Litman T; Robey RW; Aguilera A; Chakraborty AR; Reinhold WC; Basseville A; Petrukhin L; Scotto L; O'Connor OA; Pommier Y; Fojo AT; Bates SE
Mol Cancer Res; 2021 Aug; 19(8):1361-1374. PubMed ID: 34050002
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization by the histone deacetylase inhibitor PCI-24781.
Banuelos CA; Banáth JP; MacPhail SH; Zhao J; Reitsema T; Olive PL
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6816-26. PubMed ID: 18006784
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination.
Koprinarova M; Botev P; Russev G
DNA Repair (Amst); 2011 Sep; 10(9):970-7. PubMed ID: 21824827
[TBL] [Abstract][Full Text] [Related]
12. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.
Groselj B; Kerr M; Kiltie AE
Radiother Oncol; 2013 Sep; 108(3):429-33. PubMed ID: 23932191
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Hoffmann MJ; Meneceur S; Hommel K; Schulz WA; Niegisch G
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33670166
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation.
Zhang Y; Adachi M; Zou H; Hareyama M; Imai K; Shinomura Y
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):859-66. PubMed ID: 16751067
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Jain N; Odenike O
Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells.
Makita N; Ninomiya I; Tsukada T; Okamoto K; Harada S; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Oyama K; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
Oncol Rep; 2015 Sep; 34(3):1185-92. PubMed ID: 26135807
[TBL] [Abstract][Full Text] [Related]
18. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
Petrich A; Nabhan C
Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Munshi A; Tanaka T; Hobbs ML; Tucker SL; Richon VM; Meyn RE
Mol Cancer Ther; 2006 Aug; 5(8):1967-74. PubMed ID: 16928817
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
Pojani E; Barlocco D
Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
